Intravenous Bolus Topotecan in Patients with Myelodysplastic Syndrome

We treated 16 patients with myelodysplastic syndromes with 24 courses of bolus topotecan. Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m2/d, 2.0 mg/m2/d or 2.5 mg/m2/d). There was one complete response and one partial response (overall response rate 1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia & lymphoma 2001, Vol.42 (5), p.963-968
Hauptverfasser:	Seiter, Karen, Liu, Delong, Feldman, Eric J., Siddiqui, Ahmad D., Hoang, Albert, Baskind, Paul, Kancherla, Ram, Ahmed, Tauseef
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over bolus Dose-Response Relationship, Drug Female Humans Infusions, Intravenous - methods Male MDS Middle Aged myelodysplastic syndrome Myelodysplastic Syndromes - complications Myelodysplastic Syndromes - drug therapy Remission Induction Survival Rate Time Factors topotecan Topotecan - administration & dosage Topotecan - toxicity Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We treated 16 patients with myelodysplastic syndromes with 24 courses of bolus topotecan. Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m2/d, 2.0 mg/m2/d or 2.5 mg/m2/d). There was one complete response and one partial response (overall response rate 12%). Toxicity included myelosuppression, diarrhea, ileus and mucositis. There were 3 treatment-related deaths. The results of this schedule of topotecan appeared to be inferior to that reported with infusional topotecan in patients with MDS.
ISSN:	1042-8194 1029-2403
DOI:	10.3109/10428190109097715